Other Events ·
At its 2026 Annual Meeting of Stockholders held on June 18, 2026, NextCure, Inc. stockholders approved the amendment…
NXTCNextCure, Inc.
At its 2026 Annual Meeting of Stockholders held on June 18, 2026, NextCure, Inc. stockholders approved the amendment and restatement of the 2019 Omnibus Incentive Plan. This restated plan increases the maximum number of common stock shares authorized for issuance by 80,000 and modifies the evergreen provision to calculate annual increases based on outstanding shares on a fully diluted basis. Additionally, shareholders elected Anne Borgman and John G. Houston to the Board of Directors, ratified Ernst & Young LLP as the independent auditor for the 2026 fiscal year, and approved executive compensation on an advisory basis. NextCure, Inc. is a biotechnology company.